This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Pfizer Past Earnings Performance

Past criteria checks 6/6

Key information

11.09%

Earnings growth rate

12.79%

EPS growth rate

Pharmaceuticals Industry Growth	30.53%
Revenue growth rate	16.26%
Return on equity	32.74%
Net Margin	31.26%
Last Earnings Update	31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Pfizer makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:PFE Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 22	100,330	31,366	12,200	11,428
02 Oct 22	99,878	29,953	11,327	11,417
03 Jul 22	101,275	29,481	10,038	11,400
03 Apr 22	92,433	25,410	9,404	10,824
31 Dec 21	81,288	22,413	9,562	10,360
03 Oct 21	68,877	19,485	9,714	9,972
04 Jul 21	55,119	12,236	11,676	9,589
04 Apr 21	46,084	9,032	11,454	9,184
31 Dec 20	41,651	6,630	11,418	8,709
27 Sep 20	32,334	212	11,006	8,084
28 Jun 20	34,737	6,977	10,565	7,727
29 Mar 20	38,137	9,427	11,637	7,716
31 Dec 19	40,905	10,707	12,766	7,721
29 Sep 19	53,039	16,211	13,755	7,891
30 Jun 19	53,656	12,638	14,050	7,948
31 Mar 19	53,859	11,464	14,004	7,914
31 Dec 18	40,825	3,824	12,149	7,713
30 Sep 18	53,373	23,808	14,481	7,827
01 Jul 18	53,244	22,545	14,492	7,686
01 Apr 18	52,673	21,746	14,509	7,673
31 Dec 17	52,546	21,305	14,606	7,645
01 Oct 17	52,471	9,791	14,546	7,843
02 Jul 17	52,347	8,308	14,608	7,861
02 Apr 17	52,598	7,281	14,959	7,826
31 Dec 16	52,824	7,198	14,894	7,858
02 Oct 16	53,243	6,270	14,956	7,652
03 Jul 16	52,286	7,036	14,697	7,797
03 Apr 16	50,992	7,615	14,339	7,787

Quality Earnings: PFE has high quality earnings.

Growing Profit Margin: PFE's current net profit margins (31.3%) are higher than last year (27.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PFE's earnings have grown by 11.1% per year over the past 5 years.

Accelerating Growth: PFE's earnings growth over the past year (39.9%) exceeds its 5-year average (11.1% per year).

Earnings vs Industry: PFE earnings growth over the past year (39.9%) exceeded the Pharmaceuticals industry 21.1%.

Return on Equity

High ROE: PFE's Return on Equity (32.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/03/02 12:36
End of Day Share Price	2023/02/28 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pfizer Inc. is covered by 43 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

This company listing is no longer active

Pfizer Past Earnings Performance

Past criteria checks 6/6

Key information

Recent past performance updates

Full year 2022 earnings released: EPS: US$5.59 (vs US$4.00 in FY 2021)

Pfizer Inc. to Report Q4, 2022 Results on Jan 31, 2023

Third quarter 2022 earnings released: EPS: US$1.54 (vs US$1.45 in 3Q 2021)

Recent updates

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

FDA Approves Pfizer Inc.'s Supplemental New Drug Application for CIBINQO

Full year 2022 earnings released: EPS: US$5.59 (vs US$4.00 in FY 2021)

Pfizer Inc. Provides Earnings Guidance for the Financial Year 2023

Upcoming dividend of US$0.41 per share

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer's 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

Pfizer Inc. Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

Pfizer Inc. to Report Q4, 2022 Results on Jan 31, 2023

Pfizer Inc. Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial

Pfizer Inc. Declares an Increase in the Quarterly Cash Dividend on the Company's Common Stock for the First-Quarter 2023 Dividend, Payable March 3, 2023

Pfizer Inc Announces U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma